Grace Therapeutics ACST Stock
3.37 USD
{{ price }}
0.000000%
{{change_pct}}%
SECTOR
Healthcare
INDUSTRY
Biotechnology
COUNTRY
United States
Exchange
NasdaqCM
Market Cap
34.17M USD
LOW - HIGH [24H]
0.0000
-
0.0000 USD
VOLUME [24H]
0 USD
{{ volume }}
P/E Ratio
0
Earnings per share
0 USD
Grace Therapeutics Price Chart
Grace Therapeutics ACST Financial and Trading Overview
| Grace Therapeutics stock price | 3.37 USD |
| Previous Close | 2.15 USD |
| Open | 2.19 USD |
| Bid | 0 USD x 3000 |
| Ask | 0 USD x 3000 |
| Day's Range | 2.09 - 2.19 USD |
| 52 Week Range | 2.04 - 5.4 USD |
| Volume | 5.8K USD |
| Avg. Volume | 27.66K USD |
| Market Cap | 15.94M USD |
| Beta (5Y Monthly) | 1.451333 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.96 USD |
ACST Valuation Measures
| Enterprise Value | -5629209 USD |
| Trailing P/E | N/A |
| Forward P/E | -5.2195125 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.24857707 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 0.342 |
Trading Information
Grace Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.451333 |
| 52-Week Change | N/A |
| S&P500 52-Week Change | N/A |
| 52 Week High | 5.4 USD |
| 52 Week Low | 2.04 USD |
| 50-Day Moving Average | 2.75 USD |
| 200-Day Moving Average | 3.03 USD |
ACST Share Statistics
| Avg. Volume (3 month) | 27.66K USD |
| Avg. Daily Volume (10-Days) | 15.98K USD |
| Shares Outstanding | 7.45M |
| Float | 5.76M |
| Short Ratio | 0.34 |
| % Held by Insiders | 11.41% |
| % Held by Institutions | 0.38% |
| Shares Short | 18.37K |
| Short % of Float | 0.30% |
| Short % of Shares Outstanding | 0.25% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:10 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | March 31, 2023 |
| Most Recent Quarter (mrq) | June 30, 2023 |
| Next Fiscal Year End | March 31, 2024 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -10.37% |
| Return on Equity (ttm) | -49.79% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -16470000 USD |
| Net Income Avi to Common (ttm) | -41928000 USD |
| Diluted EPS (ttm) | -5.78 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 21.65M USD |
| Total Cash Per Share (mrq) | 2.91 USD |
| Total Debt (mrq) | 80K USD |
| Total Debt/Equity (mrq) | 0.13 USD |
| Current Ratio (mrq) | 12.01 |
| Book Value Per Share (mrq) | 8.609 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -16727000 USD |
| Levered Free Cash Flow (ttm) | -9177250 USD |
Profile of Grace Therapeutics
| Country | United States |
| State | QC |
| City | Laval |
| Address | 3009 boulevard de la Concorde East |
| ZIP | H7E 2B5 |
| Phone | 450-687-2262 |
| Website | https://www.acastipharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.
Q&A For Grace Therapeutics Stock
What is a current ACST stock price?
Grace Therapeutics ACST stock price today per share is 3.37 USD.
How to purchase Grace Therapeutics stock?
You can buy ACST shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Grace Therapeutics?
The stock symbol or ticker of Grace Therapeutics is ACST.
Which industry does the Grace Therapeutics company belong to?
The Grace Therapeutics industry is Biotechnology.
How many shares does Grace Therapeutics have in circulation?
The max supply of Grace Therapeutics shares is 10.14M.
What is Grace Therapeutics Price to Earnings Ratio (PE Ratio)?
Grace Therapeutics PE Ratio is 0.00000000 now.
What was Grace Therapeutics earnings per share over the trailing 12 months (TTM)?
Grace Therapeutics EPS is 0 USD over the trailing 12 months.
Which sector does the Grace Therapeutics company belong to?
The Grace Therapeutics sector is Healthcare.
Grace Therapeutics ACST included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17382.94 USD — |
+1.26
|
6.5B USD — | 17110.72 USD — | 17404.49 USD — | — - | 6.5B USD — |
| NASDAQ Capital Market Composite RCMP | 102.15 USD — |
-0.54
|
— — | 101.35 USD — | 102.39 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 923.51 USD — |
-0.73
|
— — | 917.75 USD — | 925.61 USD — | — - | — — |
| NASDAQ Composite Total Return I XCMP | 21278.67 USD — |
+1.26
|
— — | 20945.45 USD — | 21305.05 USD — | — - | — — |
- {{ link.label }} {{link}}